| Identification | Back Directory | [Name]
VPC 44116 | [CAS]
925978-30-9 | [Synonyms]
VPC 44116
Phosphonic acid, P-[(3R)-3-amino-4-[(3-octylphenyl)amino]-4-oxobutyl]- | [Molecular Formula]
C18H31N2O4P | [MOL File]
925978-30-9.mol | [Molecular Weight]
370.42 |
| Chemical Properties | Back Directory | [density ]
1.192±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
powder | [pka]
2.19±0.10(Predicted) | [SMILES]
CCCCCCCCC1=CC(NC([C@H](N)CCP(O)(O)=O)=O)=CC=C1 |
| Hazard Information | Back Directory | [Uses]
In addition to receptor-selective agonists such as SEW2871, competitive S1P receptor antagonists have provided insight into the physiological effects of S1P signaling, particularly involving S1P1. (R)-3-amino-(3-octylphenylamino)-4-oxobutylphosphonic acid (VPC44116) (S1P1/3 antagonist) and an analog, (R)-3-amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (W146) (S1P1 antagonist), both were found to increase capillary permeability as measured by Evans blue dye leakage in mouse lung tissue. This product is covered by Patent Number US 7,888,527 B2. Avanti manufactures this under license from University of Virginia |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|